June 12, 2025BMY: Bristol-Myers Squibb Co. Reports Positive Phase 3 Trial Results For Sotyktu ~1 min.Investors are taking notice of Bristol-Myers Squibb Company, as they have recently announced positive phase 3 trial results for their drug Sotyktu. This news has caused BMY shares to rise by 3....
May 14, 2025QuantWave Successfully Achieves Price Target Forecast for Bristol-Myers Squibb Company with 14.06% Profit ~2 min.QuantWave, an automated forecasting platform, recently celebrated a significant achievement in its analytics with the successful price target forecast for the stock of BRISTOL-MYERS SQUIBB COMPANY....
May 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits QuantWave Price Target with 13.0% Profit Margin ~2 min.On April 11, 2025, QuantWave, an automated forecasting platform, released a short signal for BRISTOL-MYERS SQUIBB COMPANY with a price target forecast of 44.12 $, indicating a 13....
May 8, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target as QuantWave Forecast Achieves 7.55% Profit ~1 min.BRISTOL-MYERS SQUIBB COMPANY has seen its stock reach the predicted price target set by QuantWave's automated forecasting platform....
April 10, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Forecast Target with 8.57% Profit: A Success Story for QuantWave ~2 min.BRISTOL-MYERS SQUIBB COMPANY (BMY) recently reached the price target forecasted by QuantWave, resulting in a profitable outcome for investors....
December 29, 2024Bristol Myers Squibb: Promising Results from Phase 3 Psoriatic Arthritis Trials ~1 min.Bristol Myers Squibb (BMY) recently announced positive topline results from its Phase 3 trials evaluating Sotyktu deucravacitinib in adults with psoriatic arthritis....
December 29, 2024Bristol-Myers Squibb Makes Significant Progress in Psoriatic Arthritis Treatment ~1 min.Bristol-Myers Squibb Company, a leading pharmaceutical company, has announced promising results from two Phase 3 trials evaluating the effectiveness of its new drug, Sotyktu deucravacitinib, in treating psoriatic arthritis in adults. The trials have shown that Sotyktu hits key endpoints and provides positive outcomes for patients suffering from this debilitating condition. Institutional investors ...
February 27, 2025Eli Lilly and Company Acquires Organovos FXR Program in IBD Treatment Development ~1 min.Eli Lilly and Company has recently made headlines with its acquisition of Organovos FXR Program, a significant step towards advancing treatment options for Inflammatory Bowel Disease (IBD)....
January 5, 2025Regeneron Pharmaceuticals: A Strong Performer with Promising Financials ~2 min.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been a steady performer in the biopharmaceutical industry, delivering a decent return of 89% for investors over the last five years....
January 22, 2025Jim Sees Eli Lilly and Company LLY as a Long-Term Buy ~2 min.Eli Lilly and Company, a leading pharmaceutical company, has recently caught the attention of investors, including renowned analyst Jim....
